Patient V., 66 years old, has had diabetes mellitus since age 50. Previously took oral hypoglycemic agents, then was transferred to insulin therapy; administers fixed doses of short- and intermediate-acting insulin twice daily. Admitted with complaints of constant headache, palpitations, nausea, persistently high blood pressure (up to 200/130 mmHg) poorly controlled by antihypertensive therapy (receiving ACE inhibitors, thiazide diuretics, calcium channel blockers), fever up to 39.5°C, chills, and lumbar pain that started 4 days ago. Previously, leukocytes and bacteria were detected in urine; she was repeatedly treated with antibacterial agents and uroseptics. History includes multiple hospitalizations. Objective findings: ankle edema. Lungs: vesicular breath sounds, no wheezing. Heart sounds are muffled, rhythmic; accentuated second heart sound over the aorta. BP: 180/120 mmHg, heart rate: 75 bpm. Abdomen is soft, non-tender on palpation. Liver and spleen are not enlarged. Complete blood count: hemoglobin 92 g/L, erythrocytes 3.2×10¹²/L, leukocytes 15.0×10⁹/L, band neutrophils 6%, segmented neutrophils 76%, ESR 32 mm/h. Biochemical blood test: glucose 14 mmol/L, creatinine 152 µmol/L, total protein 82 g/L, albumin 50 g/L, potassium 5.6 mmol/L, sodium 129 mmol/L, chloride 96 mmol/L, bicarbonate 20 mmol/L, cholesterol 4.6 mmol/L, LDL 3.2 mmol/L, triglycerides 1.4 mmol/L, glycated hemoglobin 9.5%. Urinalysis: specific gravity 1015, proteinuria (1.5 g protein in 24-hour urine), urine glucose 10 mmol/L, no acetone in urine, bacteriuria, 150,000 leukocytes and 1,000 erythrocytes per 1 mL of urine. Renal ultrasound: right kidney 9.8×5.2 cm, left kidney 9.4×6.0 cm. Contours are smooth. Pyramids in both kidneys are prominent with halos of increased echogenicity. Questions: 1. Suggest the most probable preliminary diagnosis. 2. Justify the diagnosis you have made. 3. Develop and justify a plan for necessary additional examination of the patient before starting therapy and during treatment. 4. What would you recommend to the patient for treating this condition? Justify your choice. 5. What actions would you take in case of no response to the therapy you prescribed? Justify your choice.
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
I now have sufficient information to provide a comprehensive answer. Let me synthesize everything from the clinical scenario and the textbook sources.
Clinical Case Analysis: Patient V., 66 y.o. with DM and Acute Febrile Illness
1. Most Probable Preliminary Diagnosis
Complicated acute bilateral pyelonephritis (against the background of type 2 diabetes mellitus, diabetic nephropathy with proteinuria, and hypertensive nephrosclerosis), clinical picture consistent with urosepsis.
Secondary diagnoses:
- Type 2 diabetes mellitus, long-standing (HbA1c 9.5% — poorly controlled), now on insulin
- Diabetic nephropathy, stage III (proteinuria 1.5 g/24h, creatinine 152 µmol/L — eGFR reduced)
- Arterial hypertension, stage 3, high cardiovascular risk, resistant hypertension
- Normocytic anemia (Hb 92 g/L) — likely of chronic inflammation + renal origin
2. Justification of the Diagnosis
Acute bilateral pyelonephritis with urosepsis is supported by the confluence of infectious, urinary, metabolic, renal, and systemic findings:
| Feature | Relevance |
|---|---|
| Fever 39.5°C, chills | Classic upper UTI / sepsis signs |
| Lumbar pain, 4 days | Bilateral renal parenchymal inflammation |
| Bacteriuria + 150,000 leukocytes/mL urine | Active urinary infection (pyuria) |
| 1,000 erythrocytes/mL urine | Hematuria from renal parenchymal damage |
| Proteinuria 1.5 g/24h | Combination of glomerular (diabetic nephropathy) + inflammatory damage |
| Creatinine 152 µmol/L | Reduced GFR — renal functional impairment |
| WBC 15×10⁹/L, band neutrophils 6% | Systemic bacterial infection / sepsis response |
| ESR 32 mm/h | Active inflammation |
| HbA1c 9.5%, glucose 14 mmol/L | Uncontrolled diabetes — major predisposing factor |
| Glucose 10 mmol/L in urine | Glucosuria provides substrate for bacterial fermentation |
| BP 200/130 mmHg, poorly controlled | Consistent with underlying hypertensive + diabetic nephropathy |
| Renal ultrasound: prominent pyramids with halos of increased echogenicity | Hallmark of medullary involvement; typical sonographic sign of acute pyelonephritis with medullary edema/ischemia |
| History of recurrent UTIs, repeated antibiotic treatment | Chronic complicated UTI course in a diabetic patient |
| Ankle edema, muffled heart sounds, accentuated S2 over aorta | Chronic hypertension, renal failure, volume overload |
| Hyponatremia (129 mmol/L), mild metabolic acidosis (HCO₃⁻ 20 mmol/L), hyperkalemia (5.6 mmol/L) | Consistent with CKD + acute septic illness |
Why diabetic patients are specifically predisposed: Glucosuria provides a fermentation substrate for gram-negative organisms (E. coli, Klebsiella), impaired neutrophil function compromises host defenses, and neuropathy may mask early symptoms allowing deeper infection. 90% of emphysematous pyelonephritis cases occur in patients with uncontrolled diabetes — Brenner & Rector's The Kidney.
The bilateral sonographic finding (prominent pyramids with hyperechoic halos in both kidneys) points to bilateral medullary involvement, distinguishing this from uncomplicated unilateral pyelonephritis and supporting the diagnosis of complicated bilateral disease in the context of diabetic nephropathy.
The resistant hypertension with this acute picture also reflects a renovascular/parenchymal basis compounded by acute infectious stress.
3. Plan for Additional Examination
Immediate (before starting therapy)
| Examination | Purpose |
|---|---|
| Urine culture with antibiogram | Identify pathogen; guide targeted antibiotic therapy (essential in recurrent/complicated UTI with prior treatment failures) |
| Blood cultures × 2 (aerobic + anaerobic) | Detect bacteremia/urosepsis; direct IV antibiotic choice |
| CT of kidneys with and without contrast (MSCT) | Rule out emphysematous pyelonephritis (gas in parenchyma), renal/perinephric abscess, urolithiasis, obstruction — CT is the most sensitive and specific modality for these complications (Brenner & Rector) |
| Serum procalcitonin, CRP | Confirm bacterial sepsis, assess severity, monitor treatment response |
| Coagulation profile (PT, aPTT, D-dimer) | Screen for DIC in the context of urosepsis |
| Serum lactate | Assess sepsis severity / tissue perfusion |
| Complete metabolic panel: urea, uric acid, eGFR (CKD-EPI) | Baseline renal function for antibiotic dosing (aminoglycosides, fluoroquinolones, carbapenems require dose adjustment) |
| ECG | Hyperkalemia (K⁺ 5.6 mmol/L) — arrhythmia risk; hypertensive heart disease assessment |
| Echocardiography | Assess LV hypertrophy, diastolic dysfunction given long-standing hypertension and muffled heart sounds |
| Urine albumin-to-creatinine ratio (ACR) | Quantify diabetic nephropathy stage |
| Urine microscopy | Characterize casts (granular, WBC casts = pyelonephritis vs. RBC casts = glomerulonephritis) |
During Treatment (monitoring)
| Examination | Purpose |
|---|---|
| Repeat urine culture 48–72 h after antibiotic initiation | Confirm sterilization |
| Repeat CBC, CRP, procalcitonin every 48 h | Monitor inflammatory response / treatment efficacy |
| Daily glucose monitoring (fingerstick + correction doses) | Infection worsens insulin resistance; intensive glycemic control needed |
| Serum creatinine, K⁺ every 48–72 h | Monitor acute kidney injury progression; nephrotoxicity surveillance |
| BP monitoring (continuous/daily) | Hypertension management in the context of acute illness |
| Repeat renal ultrasound or CT at 5–7 days if no response | Detect abscess formation, obstruction, or emphysematous change |
4. Treatment Plan
A. Hospitalization
Mandatory — this patient has urosepsis criteria: temperature 39.5°C, leukocytosis 15×10⁹/L with band shift, refractory hypertension, impaired renal function, and diabetes. The IDSA guidelines and Campbell-Walsh Urology specifically recommend hospital admission for complicated pyelonephritis requiring IV antibiotics.
B. Antibacterial Therapy
Empirical IV therapy (before culture results, then de-escalate based on antibiogram):
- First choice: IV fluoroquinolone (e.g., ciprofloxacin 400 mg IV q12h or levofloxacin 500 mg IV q24h) — excellent penetration into renal tissue, active against gram-negative uropathogens
- Alternative / broader cover: Extended-spectrum cephalosporin (ceftriaxone 2 g IV q24h) ± aminoglycoside, OR
- If resistant organisms suspected (recurrent infection, prior antibiotic use): carbapenem (imipenem-cilastatin or meropenem)
Rationale: This patient has been repeatedly treated with antibacterial agents — resistance to standard agents is likely. A carbapenem or piperacillin/tazobactam should be considered empirically. Duration: 14 days minimum for complicated pyelonephritis (Campbell-Walsh Urology). After clinical stabilization on IV therapy (typically 2–3 days afebrile), transition to oral agents guided by culture sensitivity.
Aminoglycosides should be used cautiously given existing renal impairment (creatinine 152 µmol/L) — monitor levels and adjust doses.
C. Glycemic Control
Intensify insulin therapy — target blood glucose 7–10 mmol/L in the acute setting. High glucose fuels bacterial fermentation in renal tissue (Brenner & Rector). Correct hyperosmolar or hyperglycemic state; review current fixed-dose insulin regimen and switch to flexible correction doses with basal-bolus regimen during hospitalization.
D. Antihypertensive Therapy
Continue ACE inhibitor (renoprotective in diabetic nephropathy, reduces proteinuria) and calcium channel blocker. Reassess thiazide diuretic — with eGFR reduction and acute infection, thiazides may be less effective; loop diuretic (furosemide) may be more appropriate if volume overload is present. A fourth agent (e.g., alpha-blocker doxazosin or centrally acting agent) may be added for resistant hypertension.
E. Supportive
- IV fluid resuscitation (isotonic saline) guided by hemodynamics and fluid balance — avoid overload given ankle edema and reduced kidney function
- Antipyretics (paracetamol — avoid NSAIDs given renal impairment)
- Correction of electrolyte disturbances: sodium 129 mmol/L (hyponatremia — likely dilutional in context of SIADH/sepsis), K⁺ 5.6 (mild hyperkalemia — restrict dietary K⁺, monitor for arrhythmia)
- Anemia management: investigate cause (iron studies, ferritin, B12, folate, EPO level); treat accordingly; in the acute phase, transfuse if Hb falls below 70–80 g/L
5. If No Response to Therapy (after 48–72 hours)
Definition of non-response: Persistent fever, deteriorating renal function, ongoing bacteriuria/bacteremia, or clinical worsening despite 48–72 hours of appropriate IV antibiotics.
Step 1 — Reassess and Broaden Antibiotic Coverage
- Review culture and sensitivity results; switch to targeted therapy if an organism has been identified
- If no pathogen isolated yet or resistance suspected: escalate to a carbapenem (meropenem 1 g IV q8h)
- Add antifungal coverage (fluconazole) if Candida UTI is possible (immunocompromised, prior broad-spectrum antibiotics, diabetic)
Step 2 — Urgent CT with Contrast
Non-response mandates imaging to exclude:
- Renal or perinephric abscess — requires percutaneous CT-guided drainage
- Emphysematous pyelonephritis — requires percutaneous drainage ± urgent nephrectomy
- Obstructive uropathy (calculi, pyonephrosis) — requires urgent ureteral stent or percutaneous nephrostomy
- Xanthogranulomatous pyelonephritis — chronic destructive process; may require nephrectomy
"Imaging is used to assess complications of acute pyelonephritis, including renal and perinephric abscess, emphysematous pyelonephritis, and xanthogranulomatous pyelonephritis. All of these entities are imaged best with cross-sectional imaging techniques, specifically CT." — Brenner & Rector's The Kidney
Step 3 — Interventional or Surgical Options
- Percutaneous nephrostomy or ureteral stenting: if obstruction is identified
- CT-guided percutaneous drainage: for renal or perinephric abscess; also the recommended initial approach for emphysematous pyelonephritis (Brenner & Rector: mortality 13.5% with medical management + percutaneous drainage vs. 50% with medical management alone)
- Nephrectomy: considered if:
- Uncontrolled sepsis from a non-functioning destroyed kidney
- Emphysematous pyelonephritis not responding to percutaneous drainage
- Xanthogranulomatous pyelonephritis with extensive parenchymal destruction
- Medical management and drainage fail
Step 4 — Reassess Glycemic Control
Refractory infection in diabetics is strongly linked to hyperglycemia. If glucose remains poorly controlled (>14 mmol/L), transition to IV insulin infusion protocol.
Key sources:
- Brenner and Rector's The Kidney, 2-Volume Set — Renal Infection, Emphysematous Pyelonephritis, Xanthogranulomatous Pyelonephritis
- Campbell Walsh Wein Urology, 3-Volume Set — Management of Complicated Pyelonephritis
- Smith and Tanagho's General Urology, 19th Edition — Management of Acute Pyelonephritis
This is a shared conversation. Sign in to Orris to start your own chat.